Lyme Antibodies and Research Reagents


Lyme Antibodies and Research Reagents


Lyme disease (LD) is caused by Gram-negative extracellular spirochetal bacteria from the genus Borrelia.  Borrelia is transmitted to humans by the bite from an infected hard tick belonging to one of several species of the genus Ixodes, commonly known as the deer tick. The symptoms of Lyme disease in humans occur in three stages.  In stage one of Lyme disease is often characterized by a distinctive, expanding red rash that usually develops at the site of the tick bite. Stage two (dissemination stage) occurs days to weeks following infection. At this stage the spirochetes spread hematogenously to additional body tissues. One or more of the following symptoms and signs may be noted: fatigue, chills and fever, headache, muscle and joint pain, swollen lymph nodes and secondary annular skin lesions.  Stage three typically involves intermittent episodes of joint pain. Common clinical manifestations at this stage may include meningitis, Bell's palsy, cardiac involvement, and migratory pain to joints, tendons, muscle and bone and chronic arthritis. Some symptoms and signs of Lyme disease may not appear until weeks, months, or years after a tick bite.



To assist the research community for investigating the Lyme disease both in human subjects or in animal models, Borrelia bacterial life cycle, Rockland Immunochemicals have developed a suite of antibodies to Lyme bacterial proteins that representing various stages of the infection. Following rabbit antibodies raised against recombinant proteins (CRASP-1, CRASP-2, DbpA, DbpB, ErpD/Arp37, ErpN/OspE, FlagellinOspA, OspB, OspC, p27, p35, p39, and VlsE)  have been developed.


In addition, Lyme disease control proteins are also available. 



Featured Research Antibodies targeting Lyme disease


Product Name   Catalog #   Applications   Size
 Anti-OspC (RABBIT) Antibody   200-401-C11   ELISA, WB, IHC    100 µg
 Anti-OspA (RABBIT) Antibody   200-401-C13   ELISA, WB, IHC    100 µg
 Anti-Flagellin (RABBIT) Antibody   200-401-C14   ELISA, WB, IHC    100 µg
 Anti-VlsE (RABBIT) Antibody   200-401-C33   ELISA, WB, IHC    100 µg
 Anti-Dbp-A (RABBIT) Antibody   200-401-B98   ELISA, WB, IHC    100 µg



Polyclonal Lyme



Featured Research Proteins targeting Lyme disease


Product Name   Catalog #   Applications   Size
 p35 Control Protein   000-001-C12   ELISA, WB    100 µg
 VlsE Control Protein   000-001-C33   ELISA, WB    100 µg
 Flagellin Control Protein   000-001-C14   ELISA, WB    100 µg
 OspA Control Protein   000-001-C13   ELISA, WB    100 µg
 p39 Control Protein   000-001-C17   ELISA, WB  

 100 µg


Lyme Protein


Polyclonal Lyme disease related antibodies are suitable for a variety of assays including western blotting, ELISA and lateral flow assays. 

Figure 1 shows western blot analysis of selected Lyme disease antibodies.

Western of LD Antigens


Figure1.  Western blot of LD antigens Osp C, Crasp-2 andp39.  LD antigens were expressed asFLAG-fusion proteins in E. coli andwere probed separately with corresponding anti-LD antibodies. Arrows indicate theexpected molecular weight of each antigen.



Suggested Products for Common Immunoassays

For detection of borrelial proteins by immunoassays (i.e. Western blotting, ELISA or IHC) primary rabbit host polyclonal Lyme antibodies in combination with peroxidase anti-Rabbit IgG secondary antibody are recommended.  For detection of Lyme antibodies in human sera to specific borrelial proteins of interest, the each respective Lyme disease control protein is recommended to be used. Borrelial proteins representing various stages of the infection are available for research purposes.


Lyme Polyclonal



Figure 2.  Polyclonal antibody reactivity to specificmembrane immobilized B. burgdorferiproteins in the order shown to the left.




Recombinant B. burgdorferi proteins, representative of the life cycle, are membrane-immobilized to capture antibodies in biological samples. Lateral flow technology incorporating gold colloid deposition results in band visualization indicative of a positive test.

Composition and fast, low cost and highly accurate method for detection of Lyme disease.

Current tests for Lyme disease diagnosis is time-consuming and of low accuracy. By using a set of 17 defined proteins of Lyme bacteria covering different stages of the  infection, lateral flow assays and validated test criteria, the  positive test result will be obtained in 10-20 minutes.

United States Patent pending.  Patent Application 20120142023.

To discuss licensing or custom services opportunities please contact:

Dan Kenney
Director, Scientific Business Development
(484) 791-3823

Contact Us







View our brochure about Lyme disease!


Novel Multiplex Test for Lyme disease

Novel Multiplex Test for Lyme Disease Poster





TrueBlot IP/Western Blot Mouse Rabbit Goat